BiotechTube

LY2787106

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia

Trial Timeline

Jan 1, 2010 → Dec 1, 2014

NCT ID
NCT01340976

About LY2787106

LY2787106 is a phase 1 stage product being developed by Eli Lilly for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01340976. Target conditions include Anemia.

What happened to similar drugs?

20 of 20 similar drugs in Anemia were approved

Approved (20) Terminated (5) Active (0)
✅Aranesp®AmgenApproved
✅Epoetin alfa 450 IU/kg once a week + Epoetin alfa 150 IU/kg 3 times a week + Epoetin alfa 450 IU/kg once a week (QW) + Epoetin alfa 150 IU/kg 3 times a week (TIW)Johnson & JohnsonApproved
✅Epoetin AlfaJohnson & JohnsonApproved
✅Roxadustat + rHuEPOAstraZenecaApproved
✅ICL670 + Chelation + No chelationNovartisApproved
✅cera, darbepoetin, epoetin-beta + ESARocheApproved
✅methoxy polyethylene glycol-epoetin beta [Mircera]RocheApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01340976Phase 1Completed

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40